Business Context and Reporting Period
This Form 8-K Current Report was filed by Lipocine Inc. on April 17, 2015. The filing serves as a Regulation FD disclosure regarding an upcoming presentation of clinical trial data.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure event rather than financial performance.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary event is the scheduled presentation of data from the ongoing Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study.
Outlook, Commentary, and Risks
- Upcoming Event: The Company will present data on April 19, 2015, at the American Society of Andrology 40th Annual Conference.
- Subject Matter: The presentation will evaluate the efficacy and safety of LPCN 1021, an Oral Testosterone product, in hypogonadal men with low testosterone ("Low T").
- Study Reference: The data pertains to clinical trial NCT02081300.
- Exhibits: Presentation materials are attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the specific efficacy and safety data points presented at the April 19, 2015 conference.
- Review the full text of Exhibit 99.1 for detailed clinical results.
- Confirm the status of the SOAR Phase 3 study (NCT02081300) on clinicaltrials.gov.
- Monitor subsequent filings for any impact of these results on the company's regulatory pathway or financial outlook.